Navigation Links
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Date:10/25/2007

he same periods in 2006.

Marketing, general and administrative expense was approximately $2.9 million and $8.8 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $2.6 million and $8.2 million for the same periods in 2006. The increase primarily reflects an increase in compensation costs associated with additional commercial and administrative personnel and additional stock-based compensation; offset by a decrease in consulting and outside services related to a software implementation project and strategic marketing programs expensed in 2006. Total stock-based compensation included in marketing, general and administrative expense was approximately $601,000 and $1.8 million for the three and nine months ended September 30, 2007, respectively, compared to approximately $577,000 and $1.5 million for the same periods in 2006.

As of September 30, 2007, cash, cash equivalents and short term investments were approximately $20.9 million, compared to $42.4 million at December 31, 2006. The decrease resulted primarily from net cash used to fund ongoing operations partially offset by the $10 million in gross proceeds from the registered direct offering of common stock in February 2007.

"We expect total operating expenses for the full year 2007 to be approximately $50 million, including an estimated $5 million in stock-based compensation," said Tamara A. Seymour, Chief Financial Officer of Favrille. "We believe our cash on hand along with access to our committed equity financing facility should be sufficient to fund operations through the first half of 2008."

Conference Call and Webcast Information

Favrille management will host a conference call today to discuss the third quarter 2007 financial results at 5:00 p.m. Eastern Time. A live audio webcast of management's presentation will be available at http://www.favrille.com. Alternatively, callers
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Favrille Announces Results From Study Showing Enhanced Activity From Insect Cell-Derived Immunotherapy for Lymphoma
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
5. XTL Provides Update on Phase I Clinical Trial of XTL-2125
6. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
7. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
8. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
9. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
10. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
11. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2007 - Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced ... Conference that its interim,analysis of the blinded ... the,Fast-Tracked Phase 3 clinical study of SinuNase(TM), ... in,resolution of one or both of the ...
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
Cached Medicine Technology:Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 3Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5
(Date:7/11/2014)... Ashburn, Virginia (PRWEB) July 11, 2014 ASHBURN ... 367 took effect, which allows individuals with an intellectual disability ... back of their licenses and ID cards to alert law ... with a condition. The idea was inspired by a ... proactive in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Thousands of researchers from more than ... 13-17 to reveal the latest study results, theories ... in dementia science. The Alzheimer’s Association International Conference ... kind. , As part of the Alzheimer’s Association’s ... generating new knowledge about dementia and fostering a ...
(Date:7/10/2014)... City, NY (PRWEB) July 10, 2014 ... life sciences industry, has launched a new website. ... as well as increased access to the firm’s thought ... cbpartners.com provides an ideal platform to showcase our insights, ... access issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Parents really need to stop their kids from becoming mini-couch ... dont get regular exercise are at risk of chronic ... of their study, researchers from the British Heart Foundation examined ... secondary schools in Leicester. ,They found that half ...
... conducted by a team of researchers led by Dr Peter ... ,As part of the study, researchers analysed schoolchildren who ... ,Researchers asked their parents about their kids fruit ... ,The study found that although there was no connection between ...
... of climbers have collected half a tonne of junk littered ... Monday . ,The garbage was mostly left behind ... kilos of essential items are hauled up the mountain in ... Ken Noguchi told reporters here that the expedition collected garbage ...
... exercise appears to modestly increase levels of high-density ... meta-analysis study in the issue of Archives of ... high-density lipoprotein cholesterol (HDL-C) is an independent risk ... death worldwide, according to background information in the ...
... Substituting soy nuts for other protein sources in a ... women , and also may reduce cholesterol levels in ... in the issue of Archives of Internal Medicine. ... pressure (hypertension) affects approximately 50 million Americans and 1 ...
... studying the addition of sugars to proteins ... system of insects, Karen Palter, researcher of Temple ... better understand neurodegenerative diseases in humans. Currently, her ... exploring the glycosylation process that could eventually play ...
Cached Medicine News:Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Regular Exercise may Slightly Increase HDL Levels 2Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Cryo/Cuffs can be ordered as a single ... tube assembly and insulation disk). The Cooler ...
... designed to comfortably restrict motion of ... motion of the fingers and wrist. ... splint may be trimmed using cast ... gun. One cotton stockinet is included ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: